Dynamic changes in quality of life after three first-line therapies for EGFR mutation-positive advanced non-small-cell lung cancer

Dynamic changes in quality of life after three first-line therapies for EGFR mutation-positive advanced non-small-cell lung cancer

Background: Three different tyrosine kinase inhibitors have been approved as first-line therapies for epidermal growth factor receptor (EGFR) mutation-positive advanced non-small-cell lung cancer with similar overall survival. This study determined dynamic changes in quality of life (QoL) for patien...

Full description

Bibliographic Details
Main Authors: Szu-Chun Yang, Chien-Chung Lin, Wu-Wei Lai, Sheng-Mao Chang, Jing-Shiang Hwang, Wu-Chou Su, Jung-Der Wang
Format: Article
Language:English
Published: SAGE Publishing 2018-02-01
Series:Therapeutic Advances in Medical Oncology
Online Access:https://doi.org/10.1177/1758834018755072

Internet

https://doi.org/10.1177/1758834018755072

Similar Items